Literature DB >> 8640847

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.

L Bjørge1, T S Jensen, R Matre.   

Abstract

To avoid destruction by complement, normal and malignant cells express membrane glycoproteins that restrict complement activity. These include decay-accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and protectin (CD59), which are all expressed on colonic adenocarcinoma cells in situ. In this study we have characterised the C3/C5 convertase regulators DAF and MCP on the human colonic adenocarcinoma cell line HT29. DAF was found to be a glycosyl-phosphatidylinositol-anchored 70-kDa glycoprotein. Blocking experiments with F(ab')2 fragments of the anti-DAF monoclonal antibody BRIC 216 showed that DAF modulates the degree of C3 deposition and mediates resistance to complement-mediated killing of the cells. The expression and function of DAF were enhanced by tumour necrosis factor alpha (TNF alpha) and interleukin-1 beta (IL-1 beta). Cells incubated with interferon gamma (IFN gamma) did not alter their DAF expression. Two MCP forms were expressed, with molecular masses of approximately 58 kDa and 68 kDa, the lower form predominating. MCP expression was up-regulated by IL-1 beta, but not by TNF alpha or INF gamma. Expression of DAF and MCP promotes resistance of colonic adenocarcinoma cells to complement-mediated damage, and represents a possible mechanism of tumour escape.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640847     DOI: 10.1007/s002620050269

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 3.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2.

Authors:  D R Shafren; J Gardner; V H Mann; T M Antalis; A Suhrbier
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 5.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells.

Authors:  J Nasu; M Mizuno; T Uesu; K Takeuchi; T Inaba; S Ohya; M Kawada; K Shimo; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

7.  Effect of IL-4 on altered expression of complement activation regulators in rat pancreatic cells during severe acute pancreatitis.

Authors:  Cheng Zhang; Chun-Lin Ge; Ren-Xuan Guo; San-Guang He
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

8.  Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis.

Authors:  P F Halloran; M Afrouzian; V Ramassar; J Urmson; L F Zhu; L M Helms; K Solez; N M Kneteman
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

9.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

Authors:  K L Simpson; A Jones; S Norman; C H Holmes
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

10.  Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Authors:  Robert D Loberg; LaShon L Day; Rodney Dunn; Linda M Kalikin; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.